Baxter and Mayo Clinic Launch Research and Development Collaboration to Transform Patient Care

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

 

Baxter International Inc. (NYSE:BAX), a global medical products company, and Mayo Clinic today announced a new research and development collaboration to advance innovation across a spectrum of therapeutic areas where there are high unmet patient needs.

The collaboration agreement will bring together the clinical and development expertise at Baxter and Mayo Clinic, where clinicians and researchers will work side-by-side to advance new technologies and therapies that transform patient care. The primary emphasis of the collaboration will be in areas where breakthrough treatment options can be introduced and innovation can drive access to high-quality care. The first project will focus on kidney disease, with additional projects planned in other areas. Approximately 14% of Americans have some degree of chronic kidney disease (CKD), and nearly half also have diabetes and/or cardiovascular disease – the two major causes of CKD.1

“We are excited about combining Mayo’s clinical and research expertise with Baxter’s ability to apply and scale innovation,” says Gianrico Farrugia, M.D., vice-president of Mayo Clinic and the CEO of Mayo Clinic in Florida where the collaboration will commence. “We are confident that this collaboration will help accelerate discoveries, development and application of life-changing therapies for patients.”

“Baxter is pleased to work with Mayo Clinic, a world-renowned healthcare organization that shares Baxter’s passion for advancing patient-focused innovation,” said José (Joe) E. Almeida, chairman and chief executive officer, Baxter. “The combined power of our two organizations will help us advance new solutions to the most pressing healthcare challenges, further delivering on Baxter’s mission to save and sustain lives.”

The initial agreement is for a five-year period, with a five-year renewal option. Additional details of the agreement were not disclosed.


Reference:

1 National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Accessed May 30, 2017

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.